title: Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.
abstract: We compared survival outcomes following myeloablative allotransplant (MAT) or cyclophosphamide/fludarabine (Cy/Flu) nonmyeloablative allotransplant (NMAT) for 165 patients with acute myelogenous leukemia (AML) in remission or without frank relapse. Patients who received NMAT were more likely to be older and have secondary AML and lower performance status. At a median follow-up of 61 months, median event-free survival and overall survival survival were not different between NMAT and MAT in univariate as well as multivariate analyses. Cy/Flu NMAT may provide similar disease control and survival when compared with MAT in patients with AML in remission or without frank relapse.
authors.affiliation: Division of Hematology/Oncology, Department of Medicine, Indiana University School of Medicine, Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
authors.forename: Muhammad Rizwan
authors.initials: MR
authors.lastname: Khawaja
authors.forename: Susan M
authors.initials: SM
authors.lastname: Perkins
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Schwartz
authors.forename: Michael J
authors.initials: MJ
authors.lastname: Robertson
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Kiel
authors.forename: Hamid
authors.initials: H
authors.lastname: Sayar
authors.forename: Elizabeth A
authors.initials: EA
authors.lastname: Cox
authors.forename: Gail H
authors.initials: GH
authors.lastname: Vance
authors.forename: Sherif S
authors.initials: SS
authors.lastname: Farag
authors.forename: Larry D
authors.initials: LD
authors.lastname: Cripe
authors.forename: Robert P
authors.initials: RP
authors.lastname: Nelson
mesh_terms: D000328:Adult; D000704:Analysis of Variance; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D012074:Remission Induction; D016019:Survival Analysis; D019172:Transplantation Conditioning / Q000379:methods*; D014184:Transplantation, Homologous; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D003520:Cyclophosphamide; D014740:Vidarabine; C024352:fludarabine